J8670
J8670 – Rolapitant, oral, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked
📋 J8670 summary
J8670 is a HCPCS Level II J-code used to bill Rolapitant, oral, 1 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J8670: Varubi
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ8670
DescriptorRolapitant, oral, 1 mg
Billing unitNot available in current dataset
Payment limit / unit Not available in current dataset
Mapped NDCs2
Data periodNot available in current dataset
Last updatedSource date not available
💊 About Rolapitant DRUG GUIDE
Varubi (rolapitant) is used in adults to prevent delayed nausea and vomiting that can occur after emetogenic cancer chemotherapy — including highly emetogenic regimens such as those containing cisplatin.
It is always used together with other anti-nausea medicines, not on its own.Varubi is approved for use with initial and repeat chemotherapy cycles, covering both highly emetogenic chemotherapy and moderately emetogenic chemotherapy (including anthracycline and cyclophosphamide combinations).
Clinical overview from our editorial drug guide for Rolapitant. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS
Medicare payment limit / unit
—
Est. ASP / unit
—
Est. after 2% sequester
—
HCPCS dosage
—
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly).
Full HCPCS code details (official CMS record)
Long descriptionRolapitant, oral, 1 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2017-01-01
Date added2017-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J8670 = 1 unit. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J8670 CROSSWALKED NDCs
2 NDCs map to J8670. Bill units = how many HCPCS units one package represents.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|
| 70720-0101-02 | Varubi rolapitant 90 mg/1 TABLET | TerSera | 2 TABLET in 1 BLISTER PACK (70720-101-02) | 90 mg/1 | 90 | — | ● Active | PDAC |
| 69656-0101-02 | VARUBI (FILM COATED) 90 MG | Unknown | — | — | 90 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)
Total Part B spend
$8.5K
Claims
29
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$294.46
Where J8670 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #813 of 918
#808
INTEGRA MATRIX** Q4108
$9.2K
#809
IMMPHENTIV J2373
$9K
#810
CEFAZOLIN SODIUM(J06... J0687
$9K
#811
DOXY 100* J1271
$8.6K
#812
RECARBRIO J0742
$8.5K
#813
VARUBI J8670
$8.5K
#814
LEVOFLOXACIN-D5W J1956
$8.2K
#815
PREDNISOLONE SODIUM... J7510
$7.9K
#816
GLYCOPYRROLATE(J1598... J1598
$7.6K
#817
PREHEVBRIO 90759
$7.6K
#818
GASTROGRAFIN* Q9963
$7.2K
Total claims — #878 of 918
#873
HEPAGAM B(J1571) J1571
32
#874
GAMMAGRAFT** Q4111
32
#875
TERBUTALINE SULFATE J3105
30
#876
ALHEMO PEN J7173
30
#877
ZENITH AMNIOTIC MEMB... Q4253
30
#878
VARUBI J8670
29
#879
ELLENCE J9178
29
#880
BACLOFEN(J0476)* J0476
28
#881
ARGATROBAN-0.9% NACL... J0883
28
#882
MATRION 1 SQ CM** Q4201
26
#883
DAPTOMYCIN(J0877) J0877
25
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (1)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2025 (Q1-Q4) | $8.5K | — | 29 | — | $294.46 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$5.2K
Medicare paid
$4.1K
Submitted services
3,060
Submitted charges
$13.3K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J8670 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J8670
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Not available
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J8670 billing FAQ
What is HCPCS code J8670?
J8670 is a HCPCS Level II J-code used to bill Rolapitant, oral, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
Which NDCs bill under J8670?
2 NDCs currently map to J8670 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J8670 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.